ClinicalTrials.gg
CompletedNCT00107731Updated Mar 25, 2009

Efficacy & Safety of Seroquel Plus Mood Stabilizer in the Maintenance of Bipolar I Disorder

A Phase 3 interventional study of quetiapine fumarate and lithium in Bipolar I Disorder, sponsored by AstraZeneca. Completed at 169 sites in 18 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2009-03-25.

Sponsored by AstraZeneca · Phase 3, Interventional, and Prevention

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
710
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-16

Among 57 studies testing quetiapine in Bipolar Disorder — 1 open to participants now, 1 under way, none of them phase 3. quetiapine · Bipolar Disorder.

Enrollment
3rd of 55
710 · median 92
Started
2004
with 5 others
Phase 3
24 of 57
none open now
Registered
5th of 57
by date
Lead sponsor
17 of 57
AstraZeneca

Among the 57 studies testing quetiapine in Bipolar Disorder, this one is the 3rd largest by enrollment of the 55 interventional ones that give a count, is one of 6 that started in 2004, is one of 24 in phase 3, and was the 5th registered.

Bipolar Disorder

1,685 studies on the registry are indexed under Bipolar Disorder; 267 are open to participants now.

Browse Bipolar Disorder studies →

Open to participants now

1 of the 57 studies testing quetiapine in Bipolar Disorder is open now, in 1 country. Recruiting first, the newest first:

By country, each count listing its studies:

About quetiapine

quetiapine: first FDA approval 1997 (SEROQUEL). What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 205 Bipolar Disorder studies recruiting now, 59 (29%) set no upper age limit and 134 (65%) stop at 75 or younger; 37 take children under 18; 50 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 57 studies testing quetiapine in Bipolar Disorder, or all of them as a file.
02

Study summary

The purpose of this study is to determine whether quetiapine when used as adjunct to lithium or divalproex is safe and effective in the maintenance treatment of adult patients with Bipolar I Disorder. The study consists of enrollment and 2 phases, the Open-label treatment Phase and the Randomized treatment Phase.

PLEASE NOTE: Seroquel SR and Seroquel XR refer to the same formulation. The SR designation was changed to XR after consultation with FDA.

03

Conditions studied

  • Bipolar I Disorder

Browse trials for

Keywords

  • Bipolar I Disorder
  • Manic Depressive Disorder
  • Manic Depression
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • A diagnosis of Bipolar I Disorder, Most recent episode Manic (296.4x), or Bipolar I Disorder, Most Recent Episode Depressed (296.5x), or Bipolar I Disorder, Most recent Episode Mixed (296.6x), with or without psychotic features, as defined by - Fourth Edition (DSM-IV)
  • At least 1 manic, depressed, or mixed episode in the 2 years prior to the index episode.
  • Able to understand and comply with the requirements of the study.

Exclusion criteria

Exclusion Criteria:

  • Diagnosis of an anxiety disorder as defined by , which was treated with medication within the past year.
  • Known intolerance or lack of response to quetiapine fumarate or to the assigned mood stabilizer, as judged by the investigator.
  • Previously randomized into this study or D1447C00126
Terms in these criteria, in plain language(1)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

DSM diagnostic criteria

The American Psychiatric Association’s manual of mental health diagnoses. DSM-5 (2013, revised as DSM-5-TR in 2022) replaced DSM-IV, and some studies still name the older edition. “Meets DSM criteria for …” means diagnosed by that edition’s diagnostic criteria, usually by a clinician in an interview.

05

Study design

Phase
Phase 3
Primary purpose
Prevention
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Double
Enrollment
710 participants

Interventions

06

What researchers measure

Primary outcomes

  1. Evaluate the efficacy of quetiapine versus placebo when used as adjunct therapy to mood stabilizer in increasing time to recurrence of a mood event.

Secondary outcomes

  1. Evaluate the efficacy of quetiapine versus placebo when used as a adjunct therapy to mod stabilizer in increasing time to recurrence of a manic event

07

Study locations

169 sites
  • Research Site
    Birmingham, Alabama, United States
  • Research Site
    Beverly Hills, California, United States
  • Research Site
    Chula Vista, California, United States
  • Research Site
    Redlands, California, United States
  • Research Site
    San Francisco, California, United States
  • Research Site
    Santa Ana, California, United States
  • Research Site
    Gainesville, Florida, United States
  • Research Site
    Jacksonville, Florida, United States
  • Research Site
    Miami, Florida, United States
  • Research Site
    Sarasota, Florida, United States
  • Research Site
    Tampa, Florida, United States
  • Research Site
    Winter Park, Florida, United States
  • Research Site
    Granite City, Illinois, United States
  • Research Site
    Libertyville, Illinois, United States
  • Research Site
    Schaumburg, Illinois, United States
  • Research Site
    Wichita, Kansas, United States
  • Research Site
    Metairie, Louisiana, United States
  • Research Site
    Glen Burnie, Maryland, United States
  • Research Site
    Kalamazoo, Michigan, United States
  • Research Site
    St. Charles, Missouri, United States
  • Research Site
    St. Louis, Missouri, United States
  • Research Site
    Brooklyn, New York, United States
  • Research Site
    Olean, New York, United States
  • Research Site
    Rochester, New York, United States
  • Research Site
    Morganton, North Carolina, United States
  • Research Site
    Raleigh, North Carolina, United States
  • Research Site
    Oklahoma City, Oklahoma, United States
  • Research Site
    Portland, Oregon, United States
  • Research Site
    Havertown, Pennsylvania, United States
  • Research Site
    Media, Pennsylvania, United States
  • Research Site
    Philadelphia, Pennsylvania, United States
  • Research Site
    Conroe, Texas, United States
  • Research Site
    Houston, Texas, United States
  • Research Site
    Richmond, Virginia, United States
  • Research Site
    Seattle, Washington, United States
  • Research Site
    Milwaukee, Wisconsin, United States
  • Research Site
    Greenwich, New South Wales, Australia
  • Research Site
    Brisbane, Queensland, Australia
  • Research Site
    Everton Park, Queensland, Australia
  • Research Site
    Southport, Queensland, Australia
  • Research Site
    Glenside, South Australia, Australia
  • Research Site
    Box Hill, Victoria, Australia
  • Research Site
    Dandenong, Victoria, Australia
  • Research Site
    Epping, Victoria, Australia
  • Research Site
    Richmond, Victoria, Australia
  • Research Site
    Assebroek, Belgium
  • Research Site
    Brussels, Belgium
  • Research Site
    Gent, Belgium
  • Research Site
    Kortenberg, Belgium
  • Research Site
    Manage, Belgium
  • Research Site
    St-Denijs-Westrem, Belgium
  • Research Site
    Waregem, Belgium
  • Research Site
    Kardjali, Bulgaria
  • Research Site
    Rousse, Bulgaria
  • Research Site
    Sofia, Bulgaria
  • Research Site
    Varna, Bulgaria
  • Research Site
    Jeseník, Czech Republic
  • Research Site
    Litomolice, Czech Republic
  • Research Site
    Olomouc, Czech Republic
  • Research Site
    Praha 10, Czech Republic
  • Research Site
    Praha 2, Czech Republic
  • Research Site
    Praha 6, Czech Republic
  • Research Site
    Praha 8, Czech Republic
  • Research Site
    Pterova, Czech Republic
  • Research Site
    Espoo, Finland
  • Research Site
    Harjavalta, Finland
  • Research Site
    Helsinki, Finland
  • Research Site
    Kellokoski, Finland
  • Research Site
    Seinajoki, Finland
  • Research Site
    Besancon, France
  • Research Site
    Bourg En Bresse, France
  • Research Site
    La Rochelle Cedex 1, France
  • Research Site
    Marseille Cedex 9, France
  • Research Site
    Montpellier, France
  • Research Site
    NIMES Cedex 4, France
  • Research Site
    Paris Cedex 12, France
  • Research Site
    Strasbourg Cedex, France
  • Research Site
    Toulouse, France
  • Research Site
    Augsburg, Germany
  • Research Site
    Berlin, Germany
  • Research Site
    Heidelberg, Germany
  • Research Site
    Homburg, Germany
  • Research Site
    Köln, Germany
  • Research Site
    München, Germany
  • Research Site
    Regensburg, Germany
  • Research Site
    Saarbrucken, Germany
  • Research Site
    Budapest, Hungary
  • Research Site
    Fuzesabony, Hungary
  • Research Site
    Gyor, Hungary
  • Research Site
    Kecskemet, Hungary
  • Research Site
    Kistarcsa, Hungary
  • Research Site
    Pecs, Hungary
  • Research Site
    Bari, Italy
  • Research Site
    Bergamo, Italy
  • Research Site
    Brescia, Italy
  • Research Site
    Cagliari, Italy
  • Research Site
    Civitanova Marche, Italy
  • Research Site
    Firenze, Italy
  • Research Site
    Genova, Italy
  • Research Site
    La Spezia, Italy

Showing the first 100 of 169 sites across 18 countries. Choose a country and city above to see the rest.

08

References and documents

Publications

  • Suppes T, Vieta E, Gustafsson U, Ekholm B. Maintenance treatment with quetiapine when combined with either lithium or divalproex in bipolar I disorder: analysis of two large randomized, placebo-controlled trials. Depress Anxiety. 2013 Nov;30(11):1089-98. doi: 10.1002/da.22136. Epub 2013 Jun 12. PubMed 23761037 ↗
09

Timeline

Tracking since Sep 25, 2026
Not marked actual or estimatedDates not marked actual or estimated

The record gives a start of Apr 2004 and a completion of Oct 2006. It does not say whether these dates are actual or estimated.

How these figures are worked out, and which studies are left out of them.

Registered
Apr 7, 2005
First posted
Apr 8, 2005
Start
Apr 2004
CompletionActual
Oct 2006
Last update
Mar 25, 2009
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Mar 25, 2009, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT00107731
Lead sponsor
AstraZeneca
First posted
Apr 8, 2005
Start date
Apr 2004
Completion
Oct 2006
Last update
Mar 25, 2009

Study contacts

AstraZeneca Seroquel Medical Science Director, MD
study director · AstraZeneca
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Mar 2009. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drugs tested here: Quetiapine · Lithium

Start the discussion